Blog

The Emergence of Neuromelanin-Sensitive Imaging in Parkinson’s Clinical Trials

Neuromelanin-sensitive magnetic resonance imaging (NM-MRI) has emerged as a promising biomarker for Parkinson’s disease (PD) research. Historically, imaging in PD has relied primarily on nuclear medicine techniques such as dopamine transporter (DAT) scans, as patients with PD do not exhibit robust, disease-specific patterns of brain atrophy detectable with conventional structural MRI.